الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 121 |  |  |
| | | from | 121 | | |
Abstract
Subclinical hypothyroidism is defined biochemically as a normal serum free thyroxine (T4) concentration in the presence of an elevated serum thyroid-stimulating hormone (TSH) concentration. SCH is considered to be a potential contributor to cardiac complications, also negatively affects lipid metabolism in both adults and children while more studies were needed to clear the effect on BMD. Studies addressing the indications and the effect of levothyroxine replacement therapy in SCH patients were inconclusive. In our study we aimed for disclosing the effect of SCH on cardiac parameters, lipid profile and bone density also to study the effect levothyroxine replacement therapy on those parameters. We concluded that: SCH has a negative impact on lipid profile and cardiac parameters, also on bone density. SCH patients would benefit from levothyroxine replacement therapy especially regarding cardiac parameters and lipid profile. SCH patients with TPO Ab or TG Ab had worse impact on lipid profile and cardiac parameters also have shown more benefit from levothyroxine replacement therapy.